Want to see TSE:RVV full AI Analyst Report?
Revive Therapeutics (RVV) Ratios
Revive Therapeutics Ratios
TSE:RVV's free cash flow for Q3 2026 was $-218.00. For the 2026 fiscal year, TSE:RVV's free cash flow was increased by $0.00 and operating cash flow was $-218.00. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Sep 25 | Sep 24 | Sep 23 | Sep 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.04 | 0.02 | 0.34 | 0.68 | 1.00 |
| Quick Ratio | 0.04 | 0.02 | 0.34 | 0.68 | 1.00 |
| Cash Ratio | 0.00 | 0.01 | 0.25 | 0.61 | 0.94 |
| Solvency Ratio | -0.24 | -3.01 | -1.65 | -1.76 | -4.00 |
| Operating Cash Flow Ratio | -0.04 | -0.23 | -0.99 | -1.75 | -3.13 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -130.51 | -44.81 | -120.88 |
| Net Current Asset Value | $ -4.15M | $ -3.59M | $ -2.26M | $ -1.25M | $ -298.56K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.33 | 0.00 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.00 | -0.02 | 0.00 | 0.02 | 0.03 |
| Debt-to-Capital Ratio | 0.00 | -0.02 | 0.00 | 0.02 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.02 | 0.00 | 0.01 | 0.00 |
| Financial Leverage Ratio | -0.07 | -0.06 | 1.47 | 1.34 | 1.35 |
| Debt Service Coverage Ratio | -91.53 | -2947.91 | -115.35 | -31.20 | -103.59 |
| Interest Coverage Ratio | -91.54 | -441.42 | -141.10 | -125.49 | -281.18 |
| Debt to Market Cap | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.01 | -0.00 | 0.14 | 0.34 | 0.20 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.15% |
| EBT Per EBIT | 97.08% | 667.87% | 170.98% | 114.49% | 99.85% |
| Return on Assets (ROA) | -361.23% | -5370.77% | -52.83% | -44.35% | -104.50% |
| Return on Equity (ROE) | 25.45% | 318.64% | -77.69% | -59.34% | -141.51% |
| Return on Capital Employed (ROCE) | 26.77% | 49.82% | -44.94% | -51.04% | -138.25% |
| Return on Invested Capital (ROIC) | 26.77% | 49.82% | -44.63% | -49.81% | -135.97% |
| Return on Tangible Assets | -361.23% | -5370.77% | -446.81% | -249.97% | -390.63% |
| Earnings Yield | -7.86% | -131.18% | -147.67% | -41.39% | -12.12% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3897308.10 | -2871546.25 | -2239156.42 | -2472892.68 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 3897308.10 | 2871546.25 | 2239156.42 | 2472892.68 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.02 | -0.04 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.02 | -0.04 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | -12.08 | -130.51 | -27.43 | -39.85 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -1.22% | -9.62% | -86.49% | -39.46% | -8.88% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.50 | -0.76 | -0.68 | -2.42 | -8.25 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -3.24 | -2.43 | 0.53 | 1.43 | 11.67 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -82.14 | -10.39 | -1.16 | -2.53 | -11.26 |
| Price-to-Operating Cash Flow Ratio | -82.14 | -10.39 | -1.16 | -2.53 | -11.26 |
| Price-to-Earnings Growth (PEG) Ratio | 0.14 | -0.01 | 0.03 | 0.04 | 0.32 |
| Enterprise Value Multiple | -12.34 | -0.77 | -0.54 | -2.43 | -8.09 |
| Enterprise Value | 13.01M | 8.44M | 3.01M | 13.40M | 143.50M |
| EV to EBITDA | -12.34 | -0.77 | -0.54 | -2.43 | -8.09 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -82.05 | -10.45 | -0.91 | -2.22 | -10.99 |
| EV to Operating Cash Flow | -82.05 | -10.45 | -0.91 | -2.22 | -10.99 |
| Tangible Book Value Per Share | -0.01 | -0.01 | -0.01 | -0.00 | 0.00 |
| Shareholders’ Equity Per Share | -0.01 | -0.01 | 0.02 | 0.03 | 0.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.01 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.03 | -0.01 | -0.02 | -0.06 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.97 | 1.00 | 1.00 | 1.14 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.15 | 0.07 | 0.59 | 0.95 | 0.73 |
Currency in CAD
